8-K filing — Lipocine Inc. (LPCN)
Filed: 2026-09-16 AccNo: 0001493152-26-042933 Size: 11 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
8-K filing — Lipocine Inc. (LPCN)
Filed: 2026-09-10 AccNo: 0001493152-26-042052 Size: 246 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lipocine Announces Initiation Of Phase 3 BLOOM Study Of Oral Brexanolone LPCN 1154 In Postpartum Depression, Planning About 120 Participants; First Dosing Expected Early Q4 2026
8-K/A filing — Lipocine Inc. (LPCN)
Filed: 2026-08-21 AccNo: 0001493152-26-039689 Size: 257 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Lipocine Q2 EPS $(0.32) Beats $(0.43) Estimate, Sales $190.099K Beat $156.500K Estimate
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.43) by 25.58 percent. This is a 21.95 percent increase over losses of $(0.41) per share from the